<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g347" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-345.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-341.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-342.html" >Vaccine-Preventable STDs</a><span class="carrot"> > </span>
                    <a href="lv-345.html" >Hepatitis A</a><span class="carrot"> > </span>
                    <a href="lv-345.html" >Prevention</a><span class="carrot"> > </span>Prevaccination Serologic Testing for Susceptibility
            </div>
            </br><h4 class="sgc-1" id="sigil_toc_id_347">
 Prevaccination Serologic Testing for Susceptibility
</h4>
<p>
 Approximately one third of the U.S. population has serologic&nbsp;evidence of previous HAV infection, which increases&nbsp;with age and reaches 75% among persons aged &gt;70 years. Screening for HAV infection might be cost-effective in populations&nbsp;where the prevalence of infection is likely to be high (e.g., persons aged &gt;40 years and persons born in areas of high HAV endemicity). The potential cost-savings of testing should be weighed against the cost and the likelihood that testing will interfere with initiating vaccination. Vaccination of a person who is already immune is not harmful.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

